Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead de­vel­op­ment

→ Mired in flag­ging sales for Vas­cepa, the harsh re­al­i­ties of the cur­rent cli­mate in biotech have hit Amarin as they slice 40% of the work­force — the ma­jor­i­ty of those cuts com­ing from the US com­mer­cial team. And the res­ig­na­tion of CFO Michael Kalb has led Amarin to in­stall Tom Reil­ly as his re­place­ment, ef­fec­tive June 20. Reil­ly had been fi­nance chief at Cara Ther­a­peu­tics since Oc­to­ber 2020; af­ter 14 years of fi­nan­cial roles at No­var­tis, he was Al­ler­gan’s head of fi­nance for the US gen­er­al med­i­cines unit from 2017-20. Un­der CEO Karim Mikhail, who suc­ceed­ed John Thero last year, Amarin hopes the job re­duc­tion will save them $100 mil­lion in the next year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN